Bio-Rad Laboratories, Inc.
BIO
$279.03
-$5.65-1.99%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.65% | -0.88% | -0.33% | -2.46% | -3.92% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.65% | -0.88% | -0.33% | -2.46% | -3.92% |
| Cost of Revenue | 5.69% | 2.42% | 0.70% | -4.20% | -5.74% |
| Gross Profit | -3.59% | -3.64% | -1.20% | -0.94% | -2.33% |
| SG&A Expenses | 1.42% | -0.94% | -1.70% | -4.23% | -3.92% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.83% | 0.59% | 2.46% | -1.42% | -2.47% |
| Operating Income | -8.56% | -11.50% | -18.67% | -9.67% | -13.94% |
| Income Before Tax | 142.50% | 16.18% | 126.02% | -519.65% | -175.56% |
| Income Tax Expenses | 147.28% | 26.41% | 132.39% | -382.52% | -134.16% |
| Earnings from Continuing Operations | 141.20% | 13.20% | 124.08% | -571.33% | -189.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 141.20% | 13.20% | 124.08% | -571.33% | -189.38% |
| EBIT | -8.56% | -11.50% | -18.67% | -9.67% | -13.94% |
| EBITDA | -2.51% | -5.08% | -11.18% | -5.58% | -8.56% |
| EPS Basic | 143.01% | 10.93% | 125.03% | -637.13% | -202.81% |
| Normalized Basic EPS | 0.25% | -8.22% | -16.89% | -7.15% | -15.13% |
| EPS Diluted | 142.91% | 11.09% | 124.94% | -634.96% | -202.54% |
| Normalized Diluted EPS | 0.24% | -8.18% | -16.81% | -7.05% | -14.95% |
| Average Basic Shares Outstanding | -3.36% | -3.14% | -3.22% | -3.01% | -3.41% |
| Average Diluted Shares Outstanding | -3.36% | -3.19% | -3.31% | -3.10% | -3.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |